Fasting Study of Oxybutynin Chloride Extended-Release Tablets 15 mg and Ditropan XL® Tablets 15 mg
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Oxybutynin Chloride
Extended-Release Tablets, 15 mg (Mylan Pharmaceuticals Inc.) to Ditropan XL® Extended-
Release Tablets, 15 mg (ALZA Corporation; Distributed and marketed by: Ortho-McNeil
Pharmaceuticals Inc.) following a single, oral 15 mg dose (1 x 15 mg tablet) under fasting
conditions.